STRYKER CORP
SYKAPI behind this page
SYK FY 2025 request
Playground key active
/api/financials?ticker=SYK&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 25,116 | 22,595 | +11.2% |
Show Product Lines breakouts |
|||
| Endoscopy · MedSurg and Neurotechnology | 3,133 | 2,792 | +12.2% |
| Endoscopy · MedSurg and Neurotechnology | 674 | 597 | +12.9% |
| Endoscopy · MedSurg and Neurotechnology | 3,807 | 3,389 | +12.3% |
| Hips · Orthopaedics | 1,137 | 1,059 | +7.4% |
| Hips · Orthopaedics | 728 | 645 | +12.9% |
| Hips · Orthopaedics | 1,865 | 1,704 | +9.4% |
| Instruments · MedSurg and Neurotechnology | 2,562 | 2,267 | +13.0% |
| Instruments · MedSurg and Neurotechnology | 621 | 567 | +9.5% |
| Instruments · MedSurg and Neurotechnology | 3,183 | 2,834 | +12.3% |
| Knees · Orthopaedics | 1,924 | 1,788 | +7.6% |
| Knees · Orthopaedics | 732 | 659 | +11.1% |
| Knees · Orthopaedics | 2,656 | 2,447 | +8.5% |
| Medical · MedSurg and Neurotechnology | 3,510 | 3,191 | +10.0% |
| Medical · MedSurg and Neurotechnology | 694 | 661 | +5.0% |
| Medical · MedSurg and Neurotechnology | 4,204 | 3,852 | +9.1% |
| Neuro Cranial · MedSurg and Neurotechnology | 2,052 | 1,761 | +16.5% |
| Neuro Cranial · MedSurg and Neurotechnology | 433 | 375 | +15.5% |
| Neuro Cranial · MedSurg and Neurotechnology | 2,485 | 2,136 | +16.3% |
| Neurovascular · MedSurg and Neurotechnology | 1,048 | 506 | +107.1% |
| Neurovascular · MedSurg and Neurotechnology | 920 | 801 | +14.9% |
| Neurovascular · MedSurg and Neurotechnology | 1,968 | 1,307 | +50.6% |
| Other · Orthopaedics | 596 | 504 | +18.3% |
| Other · Orthopaedics | 219 | 208 | +5.3% |
| Other · Orthopaedics | 815 | 712 | +14.5% |
| Spine · Orthopaedics | 118 | 489 | -75.9% |
| Spine · Orthopaedics | 67 | 218 | -69.3% |
| Spine · Orthopaedics | 185 | 707 | -73.8% |
| Trauma and Extremities · Orthopaedics | 2,926 | 2,586 | +13.1% |
| Trauma and Extremities · Orthopaedics | 1,022 | 921 | +11.0% |
| Trauma and Extremities · Orthopaedics | 3,948 | 3,507 | +12.6% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology | 15,647 | 13,518 | +15.7% |
| MedSurg and Neurotechnology · Non Us | 3,342 | 3,001 | +11.4% |
| MedSurg and Neurotechnology · Operating Segments | 15,647 | 13,518 | +15.7% |
| MedSurg and Neurotechnology · US | 12,305 | 10,517 | +17.0% |
| Orthopaedics | 9,469 | 9,077 | +4.3% |
| Orthopaedics · Non Us | 2,768 | 2,651 | +4.4% |
| Orthopaedics · Operating Segments | 9,469 | 9,077 | +4.3% |
| Orthopaedics · US | 6,701 | 6,426 | +4.3% |
Show Geography breakouts |
|||
| Asia Pacific | 2,164 | 2,020 | +7.1% |
| EMEA | 3,181 | 2,897 | +9.8% |
| Non Us | 6,110 | 5,652 | +8.1% |
| Other foreign countries | 765 | 735 | +4.1% |
| US | 19,006 | 16,943 | +12.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 25,116 | 22,595 | +11.2% |
| Cost of Revenue | 9,051 | 8,155 | +11.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 5,859 | 5,320 | +10.1% |
| Orthopaedics · Operating Segments | 2,570 | 2,400 | +7.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -25 | -31 | +19.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 8,429 | 7,720 | +9.2% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -25 | -31 | +19.4% |
| Gross Profit | 16,065 | 14,440 | +11.3% |
| Research & Development | 1,623 | 1,466 | +10.7% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 948 | 784 | +20.9% |
| Orthopaedics · Operating Segments | 524 | 540 | -3.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,472 | 1,324 | +11.2% |
| Selling, General & Administrative | 8,651 | 7,685 | +12.6% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 3,931 | 3,203 | +22.7% |
| Orthopaedics · Operating Segments | 3,132 | 3,111 | +0.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 7,063 | 6,314 | +11.9% |
| Amortization Of Intangible Assets | 732 | 623 | +17.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 732 | 623 | +17.5% |
| Asset Impairment Charges | 170 | 977 | -82.6% |
Show Impaired Long Lived Assets Held And Used By Type breakouts |
|||
| Long-Lived Assets and Intangible Assets | 109 | 159 | -31.4% |
| Operating Expenses | 11,176 | 10,751 | +4.0% |
| Operating Income | 4,889 | 3,689 | +32.5% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 4,672 | 4,004 | +16.7% |
| Orthopaedics · Operating Segments | 2,820 | 2,591 | +8.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 7,492 | 6,595 | +13.6% |
| Interest Expense | -607 | -409 | -48.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | 4 | -25.0% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | 3 | 4 | -25.0% |
| Non-Operating Income (Expense) | 232 | 212 | +9.4% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -44 | -35 | -25.7% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -44 | -35 | -25.7% |
| Income Before Taxes | 4,514 | 3,492 | +29.3% |
| Income Tax Expense (Benefit) | 1,268 | 499 | +154.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 6 | 8 | -25.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 10 | 8 | +25.0% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | 16 | 16 | 0.0% |
| Net Income | 3,246 | 2,993 | +8.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | 3,246 | 2,993 | +8.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 4,889 | 3,689 | +32.5% |
| EPS (Basic) | 8.49 | 7.86 | +8.0% |
| EPS (Diluted) | 8.4 | 7.76 | +8.2% |
| Wtd Avg Shares (Basic) | 382.2 | 381 | +0.3% |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 4.3 | 4.6 | -6.5% |
| Wtd Avg Shares (Diluted) | 386.5 | 385.6 | +0.2% |
| Comprehensive Income | 2,852 | 3,116 | -8.5% |
| Foreign Currency Transaction Gain Loss Before Tax (FY) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract | 102 | 106 | -3.8% |
| Foreign Exchange Contract · Cost Of Sales | 25 | 31 | -19.4% |
| Foreign Exchange Contract · Designated As Hedging Instrument | 44 | 35 | +25.7% |
| Foreign Exchange Contract · Nondesignated | 33 | 40 | -17.5% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,011 | 3,652 | +9.8% |
| Available For Sale Securities Debt Securities Current | 89 | 91 | -2.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 89 | 91 | -2.2% |
| Fair Value Inputs Level2 · Asset Backed Securities | 52 | 53 | -1.9% |
| Fair Value Inputs Level2 · US Treasury Securities | 37 | 34 | +8.8% |
| Accounts Receivable | 4,039 | 3,987 | +1.3% |
| Inventory Raw Materials And Supplies Net Of Reserves | 1,349 | 1,147 | +17.6% |
| Inventory Work In Process Net Of Reserves | 415 | 336 | +23.5% |
| Inventory Finished Goods Net Of Reserves | 3,546 | 3,291 | +7.7% |
| Inventory | 5,310 | 4,774 | +11.2% |
| Prepaid Expense Current | 1,306 | 1,593 | -18.0% |
| Total Current Assets | 14,755 | 14,847 | -0.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,876 | 3,448 | +12.4% |
Show Geography breakouts |
|||
| Asia Pacific | 97 | 75 | +29.3% |
| EMEA | 1,562 | 1,260 | +24.0% |
| Other foreign countries | 133 | 116 | +14.7% |
| US | 2,084 | 1,997 | +4.4% |
| Goodwill | 19,291 | 15,855 | +21.7% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology | 12,556 | 9,208 | +36.4% |
| Orthopaedics | 6,735 | 6,647 | +1.3% |
Show Business Acquisition breakouts |
|||
| Inari | 3,191 | — | — |
Show Reporting Unit breakouts |
|||
| Peripheral Vascular Reporting Unit | 3,203 | — | — |
| Deferred Tax Assets | 1,098 | 1,742 | -37.0% |
| Other Non-Current Assets | 3,143 | 2,684 | +17.1% |
| Total Assets | 47,844 | 42,971 | +11.3% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 27,647 | 23,115 | +19.6% |
| Orthopaedics · Operating Segments | 18,641 | 18,507 | +0.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 1,556 | 1,349 | +15.3% |
| Operating Segments | 46,288 | 41,622 | +11.2% |
| Operating Lease Right-of-Use Assets | 519 | 516 | +0.6% |
| Intangible Assets | 5,681 | 4,395 | +29.3% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 1,581 | 1,419 | +11.4% |
| Developed Technology Rights | 3,843 | 2,767 | +38.9% |
| In Process Research And Development | 34 | 34 | 0.0% |
| Other Intangible Assets | 71 | 1 | +7000.0% |
| Patents | 13 | 17 | -23.5% |
| Trademarks | 139 | 157 | -11.5% |
| Other Assets | |||
| Property Plant And Equipment Gross | 7,537 | 6,683 | +12.8% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 3,661 | 3,235 | +13.2% |
| Intangible Assets Net Excluding Goodwill | 5,681 | 4,395 | +29.3% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,799 | 1,679 | +7.1% |
| Employee Related Liabilities Current | 1,595 | 1,403 | +13.7% |
| Accrued Income Taxes Current | 418 | 539 | -22.4% |
| Dividends Payable Current | 337 | 320 | +5.3% |
| Other Liabilities Current | 2,645 | 2,266 | +16.7% |
| Debt Current | 1,000 | 1,409 | -29.0% |
| Total Current Liabilities | 7,794 | 7,616 | +2.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,859 | 12,188 | +21.9% |
| Accrued Income Taxes Noncurrent | 402 | 349 | +15.2% |
| Other Non-Current Liabilities | 2,369 | 2,184 | +8.5% |
| Total Liabilities | 25,424 | 22,337 | +13.8% |
| Operating Lease Liabilities | 348 | 379 | -8.2% |
| Deferred Tax Liabilities | -137 | -82 | -67.1% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 38 | 38 | 0.0% |
| Additional Paid In Capital Common Stock | 2,597 | 2,361 | +10.0% |
| Retained Earnings | 20,472 | 18,528 | +10.5% |
| Accumulated Other Comprehensive Income | -687 | -293 | -134.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22,420 | 20,634 | +8.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 70 | 4 | +1650.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 42 | 31 | +35.5% |
| Accumulated Other Comprehensive Income | -687 | -293 | -134.5% |
| Accumulated Translation Adjustment | -799 | -328 | -143.6% |
| Additional Paid In Capital | 2,597 | 2,361 | +10.0% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -687 | -293 | -134.5% |
| Common Stock | 38 | 38 | 0.0% |
| Retained Earnings | 20,472 | 18,528 | +10.5% |
| Total Liabilities & Equity | 47,844 | 42,971 | +11.3% |
| Common Stock Par Or Stated Value Per Share | 0.1 | 0.1 | 0.0% |
| Land Buildings And Improvements Gross | 1,793 | 1,627 | +10.2% |
| Machinery And Equipment Gross | 5,744 | 5,056 | +13.6% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 461 | 427 | +8.0% |
| Adjustment For Amortization | 732 | 623 | +17.5% |
| Stock-Based Compensation | 243 | 229 | +6.1% |
| Inventory Stepped Up To Fair Value At Acquisition | 173 | 46 | +276.1% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 173 | 46 | +276.1% |
| Deferred Income Taxes | 392 | -370 | +205.9% |
| Change in Accounts Receivable | 127 | -321 | +139.6% |
| Change in Inventory | -297 | -206 | -44.2% |
| Increase Decrease In Accounts Payable Trade | 94 | 192 | -51.0% |
| Increase Decrease In Accrued Liabilities | 318 | 74 | +329.7% |
| Increase Decrease In Accrued Income Taxes Payable | -145 | -116 | -25.0% |
| Increase Decrease In Other Operating Capital Net | -470 | -306 | -53.6% |
| Net Cash from Operations | 5,044 | 4,242 | +18.9% |
| Depreciation & Amortization | 1,570 | 1,426 | +10.1% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology · Operating Segments | 237 | 208 | +13.9% |
| Orthopaedics · Operating Segments | 423 | 433 | -2.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 178 | 162 | +9.9% |
| Operating Segments | 660 | 641 | +3.0% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -4,960 | -1,628 | -204.7% |
| Payments For Proceeds From Short Term Investments | 750 | -750 | +200.0% |
| Capital Expenditures | -761 | -755 | -0.8% |
| Proceeds From Sales Of Business Affiliate And Productive Assets | 165 | — | — |
| Other Investing Activities | -60 | 133 | -145.1% |
| Net Cash from Investing | -4,866 | -3,000 | -62.2% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 2,979 | 3,011 | -1.1% |
| Repayments Of Long Term Debt | -1,400 | -2,039 | +31.3% |
| Payments Of Dividends | -1,284 | -1,219 | -5.3% |
| Tax Withholding for Share Compensation | -149 | -195 | +23.6% |
| Proceeds From Payments For Other Financing Activities | -33 | -51 | +35.3% |
| Net Cash from Financing | 113 | -525 | +121.5% |
| Supplemental | |||
| Income Taxes Paid | 1,002 | 989 | +1.3% |
| Interest Paid | 582 | 396 | +47.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 68 | -36 | +288.9% |
| Net Change in Cash | 359 | 681 | -47.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,011 | 3,652 | +9.8% |
Values in millions USD. Source: SEC EDGAR 10-K filing.